Daewoong "We Did Not Steal Manufacturing Process" vs Medi "Nabota Must Be Disposed"

[Image source=Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] The U.S. International Trade Commission (ITC) has made a final ruling on the 'Botulinum Toxin (Botox) dispute' between Medytox and Daewoong Pharmaceutical, but it seems the conflict between the two companies remains unresolved.

On the 21st, Daewoong Pharmaceutical announced that it will address the allegations related to trade secret infringement concerning the botulinum strain and manufacturing process in domestic civil litigation as well. Medytox filed a civil lawsuit at the Seoul Central District Court in 2017, claiming that Daewoong Pharmaceutical had stolen its strain and manufacturing process.

Daewoong Pharmaceutical stated, "The ITC clearly acknowledged that there is no substantial evidence that Daewoong Pharmaceutical stole Medytox's strain," and added, "This puts an end to Medytox's claims regarding the strain."

They continued, "Currently, procedures such as spore analysis to verify Medytox's claims are underway in the domestic civil lawsuit," and expressed confidence, saying, "Since all the materials that formed the basis of the ITC's final ruling have been submitted to the domestic court, we believe the same result will be reached."

In its preliminary ruling in July, the ITC found that Daewoong Pharmaceutical had stolen Medytox's strain and manufacturing process, but in the final ruling on the 16th of this month (local time), it concluded that only the manufacturing process was involved.

Daewoong Pharmaceutical raised its voice, saying, "Medytox has not even properly clarified what trade secrets were infringed in the domestic civil lawsuit," and added, "They must clearly specify and verify in the domestic lawsuit what technology they claim was stolen from them."

On the other hand, Medytox stated that the ITC's final ruling proved that Daewoong Pharmaceutical stole its strain and manufacturing process, and based on this, it plans to accelerate the ongoing domestic litigation.

On the 18th, Medytox said, "The ITC's final ruling confirmed Daewoong Pharmaceutical's strain theft allegations," and predicted, "Since extensive scientific evidence proving Daewoong Pharmaceutical's allegations has already been submitted to the court, the domestic civil lawsuit will result in the same ruling as the ITC."

They added, "It is impossible to continue the botulinum toxin product business by falsely submitting the source of the strain," and stated, "Once the full ITC ruling is disclosed, we will win the domestic civil lawsuit and proceed with claims for damages, prohibition of use and return of the stolen strain and technology, and disposal measures against Daewoong Pharmaceutical's 'Nabota'."

This content was produced with the assistance of AI translation services.